NAFLD Among Patients With Type 2 Diabetes and CKD

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

May 6, 2019

Primary Completion Date

June 23, 2021

Study Completion Date

June 23, 2021

Conditions
Non-Alcoholic Fatty Liver DiseaseChronic Kidney DiseasesType2 Diabetes
Interventions
DIAGNOSTIC_TEST

Magnetic resonance (MR) spectroscopy of the liver

Magnetic resonance (MR) spectroscopy of the liver. Golden standard for non-invasive determination of NAFLD

DIAGNOSTIC_TEST

Fibroscan

Transient Elastography for Measurement of liver fibrosis.

DEVICE

Continuous glucose monitoring (CGM) for four days.

CGM is attached to the abdominal skin for four days. Afterwards data is converted and analysed in a computer program.

RADIATION

Dual Energy X-ray Absorptiometry (DEXA) scan

DEXA-scan of the body composition.

BIOLOGICAL

Blood samples

Immediately analyse of basic lab data. Later analyses for glucagon, amino acids, bile acids, lipidomics and metabolomics.

OTHER

Clinical and demographic data

Measurements of blood pressure, pulse, height, weight.

Trial Locations (1)

2100

Department of Nephrology, Copenhagen

All Listed Sponsors
lead

Rigshospitalet, Denmark

OTHER

NCT03826381 - NAFLD Among Patients With Type 2 Diabetes and CKD | Biotech Hunter | Biotech Hunter